Literature DB >> 25436391

Serum cytokine profiles in Takayasu's arteritis: search for biomarkers.

F Alibaz-Oner1, S P Yentür2, G Saruhan-Direskeneli2, H Direskeneli1.   

Abstract

OBJECTIVES: Assessment of disease activity is one of the major difficulties in patients with Takayasu arteritis (TAK) during follow-up. To date, no biomarker is universally accepted to be a surrogate for active disease in TAK. In this study, we aimed to investigate levels of various pro-and anti-inflammatory molecules including serum granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-6, IL-8, IL-10, IL-18 and IL-23 in patients with TAK.
METHODS: The study included 51 patients (age: 40.6±12.2 years, F/M: 45/6) with TAK and 42 age- and sex-matched healthy controls (age: 38.1±7.4 years, F/M: 38/4). All patients fulfilled the criteria of the American College of Rheumatology (ACR). TAK patients were evaluated by physician's global assessment (PGA; active/inactive) and ITAS2010 (Indian Takayasu Arteritis Clinical Activity Score) in terms of clinical activity in baseline and follow-up visits. Commercial enzyme linked immuno-sorbent assay (ELISA) kits were used for measurements of serum cytokine levels.
RESULTS: At baseline, 21 (41.2%) patients were active according to PGA and 8 (15.7%) according to ITAS2010. Serum IL-6, IL-8 and IL-18 levels were significantly higher in patients with TAK, whereas GM-CSF, IL-10, IL-23 levels were similar to healthy controls. IL-8 significantly decreased in the follow-up, associated with a decrease of clinical activity, whereas IL-23 level significantly increased. When assessed by ITAS2010 active patients had significantly higher IL-18 levels.
CONCLUSIONS: We found significantly increased IL-6, IL-8 and IL-18 levels in patients with TAK compared to healthy controls. Only IL-18 level was significantly higher in active patients assessed by ITAS2010. IL-18 was also the only cytokine in our study that correlated with CRP. These findings suggest that cytokines associated with neutrophilic, pro-inflammatory responses such as IL-6, IL-8 and IL-18 can be potential biomarkers for the assessment of disease activity in TAK and warrant further studies in larger series.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25436391

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  14 in total

1.  Single nucleotide polymorphisms of IL12B are associated with Takayasu arteritis in Chinese Han population.

Authors:  Xiaoting Wen; Si Chen; Ping Li; Jing Li; Ziyan Wu; Yuan Li; Liubing Li; Hui Yuan; Xinping Tian; Fengchun Zhang; Yongzhe Li
Journal:  Rheumatol Int       Date:  2017-02-03       Impact factor: 2.631

2.  The genetics of Takayasu arteritis.

Authors:  Paul Renauer; Amr H Sawalha
Journal:  Presse Med       Date:  2017-07-26       Impact factor: 1.228

Review 3.  Sex Differences in Pediatric Rheumatology.

Authors:  Marco Cattalini; Martina Soliani; Maria Costanza Caparello; Rolando Cimaz
Journal:  Clin Rev Allergy Immunol       Date:  2019-06       Impact factor: 8.667

4.  Identification of Susceptibility Loci in IL6, RPS9/LILRB3, and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genome-Wide Association Study.

Authors:  Paul A Renauer; Guher Saruhan-Direskeneli; Patrick Coit; Adam Adler; Kenan Aksu; Gokhan Keser; Fatma Alibaz-Oner; Sibel Z Aydin; Sevil Kamali; Murat Inanc; Simon Carette; David Cuthbertson; Gary S Hoffman; Servet Akar; Fatos Onen; Nurullah Akkoc; Nader A Khalidi; Curry Koening; Omer Karadag; Sedat Kiraz; Carol A Langford; Kathleen Maksimowicz-McKinnon; Carol A McAlear; Zeynep Ozbalkan; Askin Ates; Yasar Karaaslan; Nursen Duzgun; Paul A Monach; Huseyin T E Ozer; Eren Erken; Mehmet A Ozturk; Ayten Yazici; Ayse Cefle; Ahmet Mesut Onat; Bunyamin Kisacik; Christian Pagnoux; Timucin Kasifoglu; Emire Seyahi; Izzet Fresko; Philip Seo; Antoine G Sreih; Kenneth J Warrington; Steven R Ytterberg; Veli Cobankara; Deborah S Cunninghame-Graham; Timothy J Vyse; Omer N Pamuk; S Ercan Tunc; Ediz Dalkilic; Muge Bicakcigil; Sibel P Yentur; Jonathan D Wren; Peter A Merkel; Haner Direskeneli; Amr H Sawalha
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

5.  IL-9-producing Th9 cells may participate in pathogenesis of Takayasu's arteritis.

Authors:  Li-Li Pan; Juan Du; Na Gao; Hua Liao; Jin Wan; Wei-Ping Ci; Chun Yang; Tian Wang
Journal:  Clin Rheumatol       Date:  2016-09-15       Impact factor: 2.980

Review 6.  Mechanism and biomarkers in aortitis--a review.

Authors:  Benjamin Benhuri; Ammar ELJack; Bashar Kahaleh; Ritu Chakravarti
Journal:  J Mol Med (Berl)       Date:  2019-10-30       Impact factor: 4.599

7.  A novel susceptibility locus in the IL12B region is associated with the pathophysiology of Takayasu arteritis through IL-12p40 and IL-12p70 production.

Authors:  Toshiki Nakajima; Hajime Yoshifuji; Masakazu Shimizu; Koji Kitagori; Kosaku Murakami; Ran Nakashima; Yoshitaka Imura; Masao Tanaka; Koichiro Ohmura; Fumihiko Matsuda; Chikashi Terao; Tsuneyo Mimori
Journal:  Arthritis Res Ther       Date:  2017-09-06       Impact factor: 5.156

8.  Serum Cytokine Profile in Asian Indian Patients with Takayasu Arteritis and its Association with Disease Activity.

Authors:  Ruchika Goel; Jayakanthan Kabeerdoss; Babu Ram; John Antony Jude Prakash; Sudhir Babji; Aswin Nair; Lakshmanan Jeyaseelan; Visalakshi Jeyaseelan; John Mathew; Veeraraghavan Balaji; George Joseph; Debashish Danda
Journal:  Open Rheumatol J       Date:  2017-02-28

9.  Increased Circulating Th17 Cells, Serum IL-17A, and IL-23 in Takayasu Arteritis.

Authors:  Durga Prasanna Misra; Smriti Chaurasia; Ramnath Misra
Journal:  Autoimmune Dis       Date:  2016-03-13

10.  Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).

Authors:  Yoshikazu Nakaoka; Mitsuaki Isobe; Syuji Takei; Yoshiya Tanaka; Tomonori Ishii; Shumpei Yokota; Akira Nomura; Seitaro Yoshida; Norihiro Nishimoto
Journal:  Ann Rheum Dis       Date:  2017-11-30       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.